Alnylam Cash from 2010 to 2024

ALNY Stock  USD 250.98  6.09  2.49%   
Alnylam Pharmaceuticals Cash yearly trend continues to be fairly stable with very little volatility. Cash is likely to outpace its year average in 2024. Cash is the total amount of money in the form of currency that Alnylam Pharmaceuticals has in its possession. This includes all bills, coins, and funds in bank accounts. View All Fundamentals
 
Cash  
First Reported
2002-12-31
Previous Quarter
968.5 M
Current Value
1.1 B
Quarterly Volatility
379.3 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Alnylam Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alnylam Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 56.8 M, Interest Expense of 127.3 M or Other Operating Expenses of 2.2 B, as well as many indicators such as Price To Sales Ratio of 12.42, Dividend Yield of 0.0 or Days Sales Outstanding of 63.31. Alnylam financial statements analysis is a perfect complement when working with Alnylam Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Alnylam Pharmaceuticals Correlation against competitors.
For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

Latest Alnylam Pharmaceuticals' Cash Growth Pattern

Below is the plot of the Cash of Alnylam Pharmaceuticals over the last few years. Cash refers to the most liquid asset of Alnylam Pharmaceuticals, which is listed under current asset account on Alnylam Pharmaceuticals balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Alnylam Pharmaceuticals customers. The amounts must be unrestricted with restricted cash listed in a different Alnylam Pharmaceuticals account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. Alnylam Pharmaceuticals' Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Alnylam Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Cash10 Years Trend
Slightly volatile
   Cash   
       Timeline  

Alnylam Cash Regression Statistics

Arithmetic Mean533,894,693
Geometric Mean310,105,613
Coefficient Of Variation73.26
Mean Deviation324,885,447
Median547,178,000
Standard Deviation391,128,126
Sample Variance152981.2T
Range1.3B
R-Value0.62
Mean Square Error102400.7T
R-Squared0.38
Significance0.01
Slope53,802,796
Total Sum of Squares2141736.9T

Alnylam Cash History

2024853.3 M
2023812.7 M
2022866.4 M
2021820 M
2020496.6 M
2019547.2 M
2018420.1 M

Other Fundumenentals of Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Cash component correlations

About Alnylam Pharmaceuticals Financial Statements

Alnylam Pharmaceuticals investors use historical fundamental indicators, such as Alnylam Pharmaceuticals' Cash, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Alnylam Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash812.7 M853.3 M
Cash And Short Term Investments2.4 B2.6 B
Change In Cash-53.7 M-51 M
Free Cash Flow41.9 M44 M
Begin Period Cash Flow868.6 M912 M
Other Cashflows From Financing Activities172.1 M231.9 M
Other Non Cash Items214.9 M225.7 M
Total Cash From Operating Activities104.2 M109.4 M
Total Cash From Financing Activities172.1 M163.5 M
End Period Cash Flow814.9 M855.6 M
Total Cashflows From Investing Activities152.4 M160 M
Other Cashflows From Investing Activities-15.2 M-15.9 M
Cash And Cash Equivalents Changes61.9 M62.7 M
Cash Flows Other Operating144.5 M151.7 M
Operating Cash Flow Per Share 0.83  0.88 
Free Cash Flow Per Share 0.34  0.35 
Cash Per Share 19.53  10.34 
Capex To Operating Cash Flow 0.60  0.63 
EV To Operating Cash Flow 247.50  259.87 
EV To Free Cash Flow 614.57  645.30 
Price To Operating Cash Flows Ratio 229.54  241.02 
Price To Free Cash Flows Ratio 569.99  598.49 
Cash Ratio 0.84  0.80 
Cash Conversion Cycle 104.98  110.23 
Operating Cash Flow Sales Ratio 0.06  0.06 
Free Cash Flow Operating Cash Flow Ratio 0.40  0.38 
Cash Flow Coverage Ratios 0.04  0.05 
Price Cash Flow Ratio 229.54  241.02 
Cash Flow To Debt Ratio 0.04  0.05 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Alnylam Stock Analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.